Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng (Shenzhen) Law Firm addresses the adjustment of the grant price for the 2024 restricted stock incentive plan of Xiamen TeBao Biological Engineering Co., Ltd. and the granting of reserved restricted stocks to the incentive objects of the plan [1][2][3] Group 1: Adjustment of Grant Price - The grant price for the 2024 restricted stock incentive plan has been adjusted to 39.18 yuan per share from the previous price of 39.80 yuan per share due to a cash dividend distribution of 0.62 yuan per share [8][9][11] - The adjustment was approved by the company's board of directors and is in compliance with the relevant regulations of the Management Measures for Equity Incentives of Listed Companies and the company's incentive plan [7][10] Group 2: Reserved Stock Granting - The company plans to grant 1.2 million shares of restricted stock to 372 eligible incentive objects on September 4, 2025, at the adjusted price of 39.18 yuan per share [11][12] - The granting conditions for the reserved stocks have been met, and the company has fulfilled the necessary approval and authorization processes [10][12] Group 3: Compliance and Disclosure - The company has complied with the necessary legal and regulatory requirements for the adjustment and granting of the incentive plan, ensuring that all actions are in line with the applicable laws and regulations [10][12] - The company is required to continue fulfilling its information disclosure obligations as the incentive plan progresses [12]

上海荣正企业咨询服务（集团）股份有限公司 关于 厦门特宝生物工程股份有限公司 预留授予相关事项 之 证券简称：特宝生物 证券代码：688278 独立财务顾问报告 目 录 （二）本次实施的限制性股票激励计划与股东大会审议通过的限制性股票激 一、释义 生物工程股份有限公司 2024 年限制性股票激励计划（草案）》。 满足相应的归属条件后分次获得并登记的本公司 A 股普通股股票。 员、核心技术人员以及公司董事会认为需要激励的其他员工。 作废失效的期间 为。 足的获益条件。 必须为交易日。 息披露》 二、声明 本独立财务顾问对本报告特作如下声明： （一）本独立财务顾问报告所依据的文件、材料由特宝生物提供，本激励 计划所涉及的各方已向独立财务顾问保证：所提供的出具本独立财务顾问报告 所依据的所有文件和材料合法、真实、准确、完整、及时，不存在任何遗漏、 虚假或误导性陈述，并对其合法性、真实性、准确性、完整性、及时性负责。 本独立财务顾问不承担由此引起的任何风险责任。 （二）本独立财务顾问仅就本次限制性股票激励计划预留授予相关事项对 特宝生物股东是否公平、合理，对股东的权益和上市公司持续经营的影响发表 意见，不构成对公司的 ...

Core Viewpoint - The company conducted a self-examination regarding insider trading related to its 2025 Restricted Stock Incentive Plan, confirming that no insider trading occurred among the relevant parties during the specified period [1][3]. Group 1: Self-Examination Process - The self-examination covered the period from February 18, 2025, to August 18, 2025, focusing on stock trading activities of insider information personnel and incentive recipients [1]. - The examination was conducted in accordance with the relevant laws and regulations, with verification from the China Securities Depository and Clearing Corporation [1]. Group 2: Trading Activities of Insiders - During the self-examination period, only one entity, Guotai Junan Securities Co., Ltd., was found to have engaged in stock trading, while other insider information personnel did not engage in any trading activities [2]. - A total of 25 incentive recipients were identified to have traded the company's stock, but they acted based on publicly available information and independent judgment [2][3]. Group 3: Conclusion of Self-Examination - The company confirmed that appropriate confidentiality measures were in place during the planning and discussion of the incentive plan, and no insider trading was detected among the relevant parties [3]. - The findings align with the regulations set forth in the Management Measures for Equity Incentives, indicating no violations of insider trading laws [3].

Core Points - The company has reviewed and approved the list of incentive recipients for the 2025 Second Phase Restricted Stock Incentive Plan, confirming that all recipients meet the necessary legal and regulatory requirements [1][2] - The initial grant date for the incentive plan is set for September 5, 2025, with a price of 12.96 yuan per share for a total of 635,000 shares to be granted to 10 eligible recipients [2] Summary by Sections Incentive Plan Overview - The 2025 Second Phase Restricted Stock Incentive Plan has been established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - The plan aims to incentivize key management personnel and core staff, excluding independent directors, foreign employees, and major shareholders [2] Eligibility Criteria - The company has confirmed that all selected incentive recipients comply with the conditions outlined in the Management Measures and Listing Rules, ensuring their eligibility for the incentive plan [2] - Specific disqualifications for potential recipients include recent sanctions by the securities exchange or regulatory bodies, major legal violations, and other conditions as defined by law [1] Grant Details - The board and the remuneration committee have agreed on the legitimacy and effectiveness of the recipient list, with the conditions for the initial grant being fulfilled [2] - The total number of shares to be granted is 635,000, distributed among 10 recipients at a price of 12.96 yuan per share [2]

Core Viewpoint - The company has adjusted the grant price of the 2024 restricted stock incentive plan from 39.80 CNY per share to 39.18 CNY per share due to the implementation of the annual profit distribution plan [5][6][7]. Group 1: Decision-Making Process - The board of directors and the supervisory board approved the adjustment of the grant price during their respective meetings held on September 4, 2025 [1][5]. - The adjustment follows the procedures outlined in the company's 2024 restricted stock incentive plan draft and was authorized by the shareholders at the first extraordinary general meeting of 2024 [2][3]. Group 2: Adjustment Details - The adjustment was made based on the profit distribution plan approved at the 2024 annual general meeting, which included a cash dividend of 0.62 CNY per share [6]. - The formula used for the adjustment is P = P0 - V, where P0 is the original grant price, V is the cash dividend per share, and P is the adjusted grant price [6]. Group 3: Impact of Adjustment - The adjustment of the grant price is a result of the annual profit distribution and will not have a substantial impact on the company's financial status or operating results [6][7]. - The supervisory board confirmed that the adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [7]. Group 4: Legal Opinions - The company has obtained necessary approvals for the adjustment, ensuring compliance with relevant regulations and guidelines [7][8]. - The conditions for the reserved portion of the incentive plan have been met, and the company will continue to fulfill its information disclosure obligations as the incentive plan progresses [8].

证券代码：300644 证券简称：南京聚隆 公告编号：2025-102 债券代码：123209 债券简称：聚隆转债 南京聚隆科技股份有限公司 关于向 2025 年第二期限制性股票激励计划激励对象 首次授予限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： ? 限制性股票首次授予数量：63.50 万股 ? 限制性股票首次授予价格：12.96 元/股 ? 股权激励方式：第二类限制性股票 南京聚隆科技股份有限公司（以下简称"公司"）2025 年第二期限制性股票 激励计划规定的限制性股票首次授予条件已成就，根据公司 2025 年第二次临时 股东大会的授权，公司于 2025 年 9 月 5 日召开了第六届董事会第十七次会议， 会议审议通过了《关于向 2025 年第二期限制性股票激励计划激励对象首次授予 限制性股票的议案》，确定以 2025 年 9 月 5 日为首次授予日，向 10 名激励对象 授予限制性股票 63.50 万股，授予价格为 12.96 元/股。现将有关事项说明如下： 一、激励计划简述 （一）激励工具：第二类限制性股票 （二）标 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-029 厦门特宝生物工程股份有限公司 第九届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第九届董事会第十一 次会议于 2025 年 9 月 4 日以现场会议结合通讯表决的方式召开。全体董事一致 同意豁免本次会议通知的期限要求，并已在董事会会议上就豁免通知时限的相关 情况做出说明。本次会议由董事长孙黎先生主持，会议应出席董事 9 名，实际出 席董事 9 名，董事会秘书、部分监事及其他高级管理人员列席本次会议。本次会 议的召集和召开程序符合《公司法》和《公司章程》等有关规定，会议决议合法、 有效。 二、董事会会议审议情况 （一）审议通过《关于调整 2024 年限制性股票激励计划授予价格的议案》 鉴于公司 2024 年年度权益分派方案已于 2025 年 5 月 9 日实施完毕，以方案 实施前的公司总股本 406,800,000 股为基数，每股派发现金红利 0.62 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-030 厦门特宝生物工程股份有限公司 第九届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 部分限制性股票的议案》 经认真审议，监事会认为： 规定的禁止实施股权激励计划的情形，公司具备实施股权激励计划的主体资格。 人民共和国证券法》等法律、法规和规范性文件规定的任职资格，符合《上市 公司股权激励管理办法》及《上海证券交易所科创板股票上市规则》规定的激 励对象条件，符合公司《2024 年限制性股票激励计划（草案）》及其摘要规定 的激励对象范围，其作为公司 2024 年限制性股票激励计划预留授予激励对象的 主体资格合法、有效。 以及公司《2024 年限制性股票激励计划（草案）》及其摘要中有关授予日的相 关规定。 厦门特宝生物工程股份有限公司（以下简称"公司"）第九届监事会第八 次会议于 2025 年 9 月 4 日以现场结合通讯表决的方式召开。经全体监事同意， 一致豁免本次会议通知的期限要求，并已在会议上就豁免通知 ...

Group 1 - The company held an emergency meeting of the Supervisory Board on September 5, 2025, with all three supervisors present, and the meeting was conducted in accordance with relevant laws and regulations [1][2] - The Supervisory Board approved the adjustment of the reserved grant price for the 2025 restricted stock incentive plan to 2.24 yuan per share, allowing for the grant of 886,000 shares to three eligible recipients [2][3] - The list of recipients for the reserved grant under the incentive plan was verified to meet all legal qualifications and did not include any individuals disqualified under relevant laws and regulations [3]

Core Viewpoint - The company has announced the public disclosure and verification opinions regarding the 2025 Restricted Stock Incentive Plan, which was approved by the board of directors on August 25, 2025 [1]. Disclosure Situation - The public disclosure includes the names and positions of the incentive plan participants [2] - The disclosure period is from August 27, 2025, to September 5, 2025 [2] - The disclosure method is through the company's public bulletin board [2] - Employees can provide feedback in writing or via email during the disclosure period [2] - No objections were received regarding the proposed list of incentive participants by the end of the disclosure period [2] Verification Situation - The board's remuneration and assessment committee verified the list of proposed incentive participants, including their identification documents, employment contracts, and positions within the company [2][3] Verification Opinions - The incentive participants meet the qualifications as stipulated by the Company Law, Securities Law, Management Measures, Listing Rules, and other relevant regulations [3] - The proposed participants do not fall under any disqualifying conditions as per the Management Measures [3] - The participants include core technical/business personnel and other individuals deemed necessary for incentives, excluding independent directors and major shareholders [3] - The basic information of the incentive participants is accurate, with no falsehoods or significant omissions [3]